Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2001-04-19
2002-10-22
Stucker, Jeffrey (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S323000, C530S324000, C530S387100, C530S388300, C530S388400
Reexamination Certificate
active
06469143
ABSTRACT:
The present invention relates to an antigen/antibody specificity exchanger, which comprises an amino-acid sequence which specifically binds to a certain antigen linked to an amino-acid sequence to which a certain antibody binds. In vitro the antigen/antibody specificity exchanger of the invention can be used as a diagnostic reagent instead of antisera or monoclonal antibodies in testing systems, and in vivo it can be used to redirect antigens or antibodies to other antibodies or antigens, respectively, than they were originally directed to.
BACKGROUND
During the past decade the antigenic structure of several viral proteins have been characterized using synthetic peptides, such as the human immunodeficiency virus-1(HIV-1)gp160, and the hepatitis B virus core/e antigens (HBc/eAg). Recently it has been shown that a synthetic peptide corresponding to the complementarity determining region 3 of the heavy chain (CDRH3) of a monoclonal antibody (mAb; F58), directed to the variable third (V3) domain of HIV-1 gp160, may act as a mini antibody and neutralize HIV-1 in vitro. In the experimental part of the present specification, the construction of synthetic peptides combining the CDRH3 domain of the mAb F58, or CDRH1, CDRH2, CDRH3 domain of Ab C1-5, and antigenic regions derived from the HIV-1 gp41, HBc/e antigen, hepatitis C virus (HCV) core protein or from the poliovirus VP1, is shown. These peptides specifically bound the V3 domain of HIV-1. Thus, it was possible to modify the antigenic surface of HIV-1 V3 peptides. This antigen/antibody specificity exchanger will be used for redirecting the reactivity of circulating antibodies and using already existing antibody specificities for a predetermined purpose. It may also serve to alter the composition of the surface of proteins by the addition of foreign determinants. For example, the widely used poliovirus vaccination, together with the high rate of seropositivity to enteroviral proteins may be a suitable pool of antibodies to redirect against other pathogens, such as HIV.
The complementary determining regions (CDRs) of antibodies are responsible for the specificity of the antibody (1,2). X-ray crystallography has shown that the three CDRs of the variable (V) region of the heavy chain and the three CDRs of the V region of the light chain may all have contact with the epitope in an antigen-antibody complex (3). Single peptides corresponding to the CDRs of mAbs to various antigens have been shown to mimic the recognition capabilities of the respective mAb (4-10). Recently it was shown that a peptide corresponding to CDRH3 of a mAb specific for the V3 region of human immuno deficiency virus-1, holds neutralizing capacity when assayed in vitro (9). It was also observed that the CDRH2 of a mAb to hepatitis B core antigen (HBcAg) is capable of capturing HBcAg (10).
REFERENCES:
patent: 5091513 (1992-02-01), Huston et al.
patent: 5196510 (1993-03-01), Rodwell et al.
patent: 5260189 (1993-11-01), Formoso et al.
patent: 0 182 546 (1986-05-01), None
patent: WO 93/15210 (1993-08-01), None
patent: WO 94/13804 (1994-06-01), None
patent: WO 95/08577 (1995-03-01), None
Bianchi, et al.,Int J Pept Protein Res, 41(4): 385-393, Apr. 1993, “Chemical Synthesis of a Designed Beta-Protein Through the Flow-Polyamide Method.”.
Bianchi, et al.,Int J Pept protein Res, 42(1):93-96, Jul. 1993, “Affinity Purification of a Difficult-Sequence Protein: Implications for the Inclusion of Capping in Synthetic Protocols.”.
Holliger, et al.,Proc Natl Acad Sci USA, 90:6444-6448, Jul. 1993, “‘Diabodies’: Small Bivalent and Bispecific Antibody Fragments.”.
Levi, et al.,Proc Natl Acad Sci USA, 90: 4374-4378, May 1993, “A Complementarity-Determining Region Synthetic Peptide Acts as a Miniantibody and Neutralizes Human Immunodificiency Virus Type 1 in vitro”.
Saragovi, et al.,Science, 253: 792-795, Aug. 16, 1991, “Design and Synthesis of a Mimetic from an Antibody Complementarity-Determining Region.”.
Tramontano, et al.,J of Molecular Recognition, 7(1): 9-24, 1994, “The Making of the Minibody: An Engineered Beta-Protein for the Display of Conformationally Constrained Peptides”.
Zanetti, M.,Nature, 355: 476-477, Jan. 30, 1992, “Antigenized Antibodies”.
Barbas, Carols, et al., “Assembly of combinatorial antibody libraries on phage surfaces: The gene III site,”Proc. Natl. Acad. Sci. USA, vol. 88, pp. 7978-7982, Sep. 1991.
Knobbe Martens Olson & Bear LLP
Stucker Jeffrey
Tripep AB
LandOfFree
Antigen/antibody specificity exchanger does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigen/antibody specificity exchanger, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen/antibody specificity exchanger will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2998362